Second Opinion

POST-TESTSecond Opinion: Proceedings from a Two-Part CME Satellite Symposia SeriesHeld at the 31 st Annual San Antonio Breast Cancer Symposium and Interviewswith the Faculty — December 12-13, 2008Q UE S TIONS ( P LE A SE CIRCLE A NSWER) :1. In a randomized study reported byO’Shaughnessy and colleagues, thecombination of lapatinib and trastuzumabresulted in equivalent progression-freesurvival compared to lapatinibalone for heavily pretreated patients withHER2-positive metastatic breast cancerprogressing on trastuzumab.a. Trueb. False2. In a Phase III study by von Minckwitzand colleagues, continuation of trastuzumabcombined with capecitabineresulted in improvements in_____________ compared to capecitabinealone in patients with HER2-positivemetastatic breast cancer progressing onprior trastuzumab.a Time to progressionb. Response ratec. Clinical benefit rated. All of the above3. In CALGB-40502, which of the followingchemotherapy agents are beingevaluated in combination with bevacizumabas first- or second-line therapyfor patients with locally recurrent ormetastatic breast cancer?a. Weekly paclitaxelb. Weekly nab paclitaxelc. Weekly ixabepiloned. Both a and be. a, b and c4. In EFECT, fulvestrant resulted inequivalent time to disease progressioncompared to exemestane in postmenopausalpatients with ER/PR-positivemetastatic breast cancer after treatmentwith a prior nonsteroidal aromataseinhibitor.a. Trueb. False5. In the TransATAC analysis, the OncotypeDX Recurrence Score predicted thelikelihood of distant metastatic diseasethrough nine years of follow-up forpatients who received tamoxifen oranastrozole.a. Trueb. False6. In the meta-analyses of the trialsevaluating the role of adjuvant aromataseinhibitors, aromatase inhibitors in bothup-front and switching strategies significantlyreduced the risk of relapse.a. Trueb. False7. In an analysis of endocrine symptomsreported at the first follow-up visit in theATAC trial, women who experienced____________ had a lower breast cancerrecurrence rate.a. Vasomotor symptomsb. Joint symptomsc. Vaginal symptomsd. Both a and be. All of the above8. In the NOAH trial, evaluating neoadjuvantchemotherapy with or withouttrastuzumab for patients with locallyadvanced, HER2-positive breast cancer,the pathologic complete response ratefor patients who received trastuzumabwas _________ as compared to 23percent for those who did not.a. 17 percentb. 29 percentc. 36 percentd. 43 percent9. T-DM1 is a novel agent that combines amaytansine derivative with ___________.a. Docetaxelb. Trastuzumabc. Bevacizumabd. None of the abovePost-test answer key: 1b, 2d, 3e, 4a, 5a, 6a, 7d, 8d, 9b18